Headquartered in Cambridge, MA Fiscal year ends December NASDAQ: WVE wavelifesciences.com
Wave Life Sciences (Nasdaq: WVE) is a clinical-stage biotechnology company focused on developing RNA medicines to treat both rare and common disorders. The company's proprietary PRISM platform combines multiple RNA-targeting modalities — including RNAi (SpiNA) and RNA editing (AIMers) — with chemistry innovation and human genetics insights. Wave's lead clinical pipeline includes WVE-007 (an INHBE-targeting GalNAc-siRNA for obesity), WVE-006 (a GalNAc-conjugated RNA editing oligonucleotide for alpha-1 antitrypsin deficiency), and WVE-008 (an RNA editing AIMer for PNPLA3 I148M liver disease). The company also has a strategic research collaboration with GSK leveraging its siRNA technology with SpiNA design for hepatic and extra-hepatic targets, as well as several preclinical programs. Wave's revenue is primarily derived from its GSK collaboration. Updated
Wave Life Sciences has lost nearly 70% of its value this year, yet its RNA platform spans obesity, rare liver disease, and genetic disorders in ways that could make it irresistible to…
Wave Life Sciences (NASDAQ:WVE) shares are trading near historic lows after two Wall Street firms cut their price targets following updated Phase 1 INLIGHT trial data for WVE-007, the company’s obesity candidate.…
Joel South Secondary offerings from biotechs Immunovant, Kymera Therapeutics, and Wave Life Sciences prompted some huge insider buying recently.
Wave Life Sciences (Nasdaq: WVE) is a clinical-stage biotechnology company focused on developing RNA medicines to treat both rare and common disorders.
The Wall Street consensus 12-month price target for WVE is $17.68.
